

Condensed Interim Consolidated Financial Statements

For the Three and Six Months Ended May 31, 2023 and 2022

(Expressed in Canadian Dollars)

(Unaudited)

NOTICE TO READER

The accompanying condensed interim consolidated financial statements of Better Plant Sciences Inc. ("the Company") have been prepared by management in accordance with International Financial Reporting Standards ("IFRS"). Management acknowledges responsibility for the preparation and presentation of the condensed interim consolidated financial statements, including responsibility for significant accounting estimates and the choice of accounting principles and methods that are appropriate to the Company's circumstances. These unaudited condensed interim consolidated financial statements have not been reviewed by the Company's independent auditor.

Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars)

		May 31, 2023	November 30, 2022
	Notes	(unaudited)	
Assets			
Current assets		4.040	E 4 7 4 4
Cash	0	4,643	54,741
Marketable securities	3	22,007	75,405
Amounts receivable	_	41,990	-
Net investment in sublease	5	-	39,565
Prepaid expenses and deposits		-	1,851
Total current assets		68,640	171,562
Non-current assets			
Investment in associates	4	1,203,198	1,206,547
Due from related parties		(9,313)	54,363
Leasehold improvements	6		8,208
Total non-current assets		1,193,885	1,269,118
Total assets		1,262,525	1,440,680
Liabilities			
Current liabilities			
Accounts payable and accrued liabilities		910,232	914,441
Due to related parties		85,342	166,812
Deferred revenue and customer deposit		-	50,000
GST payable		122,809	121,289
Convertible debentures and interest payable	7	976,899	851,513
Lease liabilities	5	-	29,848
Loan payable	18	119,211	-
Total current liabilities		2,214,493	2,133,903
Non-current liabilities			
Loan payable	18	-	118,422
Total liabilities		2,214,493	2,252,325
Shareholders' equity			
Share capital	9	28,560,928	28,560,928
Equity reserves	11	10,829,681	10,828,717
Reserve for convertible debentures	7	34,041	34,041
Deficit		(40,376,618)	(40,235,331)
Total shareholders' equity		(951,968)	(811,645)
Total liabilities and shareholders' equity		1,262,525	1,440,680
• •			

Nature of operations and continuance of business (Note 1) Commitments and contingencies (Note 18) Subsequent event (Note 19)

Approved and authorized for issuance on behalf of the Board of Directors on July 31, 2023:

_/s/ "Bruce Mullen"	_/s/ "Cole Drezdoff"
Director	Director

Condensed Interim Consolidated Statements of Operations (Expressed in Canadian Dollars) (Unaudited)

		Three mont May 3		Six month: May 3		
	Notes	2023	2022	2023	2022	
Revenue Cost of revenue Gross profit	8	10,000 7,500 2,500	184,474 60,638 123,836	83,675 66,440 17,235	309,036 149,938 159,098	
Expenses Advertising, marketing and media Consulting fees Depreciation Listing fees Office and administration Professional fees Share-based compensation Wages Total expenses	11 8	13,900 - 2,250 12,396 40,150 134 62,889 131,719	46,868 26,700 24,759 8,210 39,719 46,800 (18,001) 137,533 312,588	626 38,734 6,332 3,750 31,009 40,150 963 88,477 210,041	95,190 153,783 49,533 10,210 93,109 95,749 49,471 249,093 796,138	
Net loss before other items		(129,219)	(188,752)	(192,806)	(637,040)	
Other items Investment loss Other income (expenses) Net loss from continuing operations	14 15	(36,299) 37,071 (128,447)	(400,758) (58,268) (647,778)	(52,595) 104,114 (141,287)	(613,576) (122,904) (1,373,520)	
Loss from discontinued operations Net loss	17	(128,447)	(101,759) (749,537)	- (141,287)	(374,789) (1,748,309)	
Loss per shares from continuing operations, basic and diluted discontinued operations, basic and diluted Weighted average shares outstanding, basic and diluted		(0.01) - 19,917,970	(0.03) (0.01) 19,917,970	(0.01)	(0.07) (0.02) 19,917,970	

Condensed Interim Consolidated Statements of Changes in Equity (Expressed in Canadian Dollars) (Unaudited)

	Notes _	Share capital Number of shares	Amount \$	Equity reserves \$	Shares issuable \$	Reserve for Convertible debentures \$	Accumulated other Comprehensive income (loss)	Deficit \$	Total Shareholders' equity \$
Balance, November 30, 2021 Fair value of stock options granted Realized foreign exchange loss Reclassification of shares issuable Net loss for the period Balance, May 31, 2022	-	19,917,970 - - - - 19,917,970	28,560,928 - - - - - - 28,560,928	10,768,338 49,471 - - - 10,817,809	31,420 - - - - - 31,420	34,041 - - - - - 34,041	(18,387) - 18,387 - -	(37,924,622) - - - (1,748,309) (39,672,931)	1,451,718 49,471 18,387 - (1,748,309) (228,733)
Balance, November 30, 2022 Fair value of stock options granted Net loss for the period Balance, May 31, 2023	11 -	19,917,970 - - - 19,917,970	28,560,928 - - 28,560,928	10,828,717 964 - 10,829,681	- - - -	34,041	- - - -	(40,235,331) - (141,287) (40,376,618)	(811,645) 964 (141,287) (951,968)

Condensed Interim Consolidated Statements of Cash Flows (Expressed in Canadian Dollars) (Unaudited)

` ,		Six months end	led May 31,
	Notes	2023	2022
Operating activities:			
Net Loss from continuing operations		(141,287)	(1,373,520)
Items not involving cash:			
Accretion on convertible debt	7	78,820	74,259
Amortization and depreciation		8,208	49,534
Dilution gain on equity accounted investee		-	(17, 173)
Gain on sale of equity accounted investee		-	(130,000)
Gain on settlement of debt	15	(231,255)	-
Interest on convertible debentures	7	46,566	67,315
Interest expense on lease liability	5	-	7,567
Interest expense on government loans		-	104,177
Interest income on sublease	5	(2,620)	-
Loss on sale of marketable securities		-	(43,924)
Loss on disposal of subsidiary		_	21,099
Share of net loss of equity accounted investee	4	3,222	512,284
Share-based compensation	11	964	49,471
Realized loss on marketable securities		1,875	-
Unrealized loss on marketable securities		47,498	292,389
Changes in non-cash operating working capital:		17,100	202,000
Accounts receivable		_	(108,411)
Prepaid expenses & other assets		1,851	82,010
Due from related parties		63,676	(35,663)
Accounts payable and accrued liabilities		(2,689)	221,656
Due to related parties		108,584	18,890
Deferred revenue		(50,000)	30,276
Net cash used in operating activities - continuing operations		(66,588)	(177,764)
Net cash provided by operating activities - discontinued operations		(00,300)	(67,962)
Their cash provided by operating activities - discontinued operations			(07,902)
Investing activities:			
Proceeds from sale of marketable securities	3	4,025	184,040
Proceeds from sale of equity accounted investee	4	128	150,000
Sublease payments received	5	42,186	-
Net cash provided by investing activities	O	46,338	334,040
Net cash provided by investing activities - discontinued operations			6,588
The cash provided by investing activities - discontinued operations			0,000
Financing activities:			
Lease payments	5	(29,848)	(46,274)
Convertible debenture interest payments		-	(22,438)
Net cash used in financing activities - continuing operations		(29,848)	(68,712)
Net cash used in financing activities - discontinued operations		(20,0.0)	(27,041)
The coordinate of the manner of the coordinate o			(21,011)
Effect of foreign exchange on cash			18,387
Chang in cash		(50,098)	17,536
Cash, beginning of period		54,741	24,562
Cash, end of period		4,643	47,347
Cash, end of period		4,043	41,041

(The accompanying notes are an integral part of these condensed interim consolidated financial statements)

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

1. Nature of Operations and Going Concern

Better Plant Sciences Inc. ("Better Plant" or the "Company") was incorporated under the laws of the province of British Columbia, Canada, on November 28, 2014 as 1020439 BC Ltd. On August 18, 2020, the Company changed its name to Better Plant Sciences Inc. The Company provides consulting and other business services. The head office of the Company is located at Unit 1 - 2770 Fraser Street, Vancouver, British Columbia, Canada.

These condensed interim consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes that the Company will be able to realize its assets and satisfy its liabilities in the normal course of business for the foreseeable future.

The Company has incurred a net loss from continuing operations of \$141,287 and used \$66,588 of cash in operating activities from continuing operations during the six months ended May 31, 2023. As at May 31, 2023, the Company had a working capital deficiency of \$2,145,853 including cash of \$4,643 and had an accumulated deficit of \$40,376,618. The Company had limited cash reserves at May 31, 2023, and currently relies on issuing new debt and equity instruments to fund its operations until the growth in its business generates sufficient cash flow from operations. The continued operations of the Company are dependent on future profitable operations, management's ability to manage costs, and the future availability of equity or debt financing. Whether and when the Company can generate sufficient operating cash flows to pay for its expenditures and settle its obligations as they fall due is uncertain. The terms of any future debt or equity issuance may be at terms that are unfavorable to the Company. These factors, among others, could have a significant impact on the Company's operations. These material uncertainties may cast significant doubt upon the Company's ability to continue as a going concern.

These condensed interim consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and the consolidated statement of financial position classifications that would be necessary were the going concern assumption be inappropriate. These adjustments could be material.

2. Significant Accounting Policies

(a) Statement of Compliance

These condensed interim consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and the interpretations of the International Financial Reporting Interpretations Committee.

(b) Basis of Presentation and Principles of Consolidation

These condensed interim consolidated financial statements include the accounts of the Company and its subsidiaries, including 100% owned subsidiary Metaversive Holdings Inc. ("Metaversive Holdings") (previously Urban Juve Provisions Inc. ("Urban Juve") amalgamated with 100% owned subsidiary Jusu Bars Corp. ("Jusu Bars"), 100% owned subsidiary 1233392 B.C. Ltd. (formerly Jack n Jane Essentials Inc.) and formerly owned subsidiaries Jusu Wellness Inc. ("Jusu Wellness") until the date of sale on April 20, 2022, and W & W Manufacturing Inc. ("W&W Manufacturing") until the date of dissolution on February 14, 2022. All intercompany balances and transactions have been eliminated on consolidation.

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

2. Significant Accounting Policies (continued)

(b) Basis of Presentation and Principles of Consolidation (continued)

These condensed interim consolidated financial statements have been prepared on a historical cost basis. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting, except for the cash flow information. The presentation and functional currency of the Company is the Canadian dollar.

In the opinion of the Company's management, all adjustments considered necessary for a fair presentation have been included.

(c) Significant Accounting Estimates and Judgments

The preparation of these condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

Significant areas requiring the use of estimates include:

- impairment of inventory
- useful lives and carrying values of equipment and intangible assets
- impairment of investments in associates and marketable securities
- fair value of share-based compensation
- measurement of unrecognized deferred income tax assets

Significant judgments made by management in the application of IFRS that have a significant effect on the condensed interim consolidated financial statements include the following:

Going concern

The factors that are used in determining the application of the going concern assumption which requires management to consider all available information about the future, which is at least but not limited to 12 months from the year end of the reporting period.

Incremental borrowing rate

Judgment was used to determine the incremental borrowing rate for lease liabilities under IFRS 16. The incremental borrowing rate applied to the lease liabilities was 16%. The rate was estimated based on the Company's ability to source debt financing to fund its operations.

(d) Future Accounting Pronouncements

Certain pronouncements have been issued by the IASB, or the IFRS Interpretations Committee that are not mandatory for the current period and have not been early adopted. Management has assessed that there are no other future accounting pronouncements that are expected to have a material impact on the Company's financial statements in the current or future reporting periods.

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

3. Marketable Securities and Investments

As at May 31, 2023, the Company holds 215,444 shares of *Komo Plant Based Foods Inc.* ("Komo YUM") (November 30, 2022 – 215,444). Below is a summary of changes in the Company's marketable securities and investments for the six months ended May 31, 2023 and 2022:

	November 30,			Realized		May 31,
	2022	Expiry of	Proceeds	gain (loss)	Unrealized	2023
	fair value	warrants	from sale	on sale	gain (loss)	fair value
Komo YUM-Shares	75,405	-	_	_	(53,398)	22,007
	November 30,			Realized		May 31,
	2021	Expiry of	Proceeds	gain (loss)	Unrealized	2022
	fair value	warrants	from sale	on sale	gain (loss)	fair value
Komo YUM-Shares	550,782	-	(184,040)	44,140	(292,389)	118,493
Komo YUM-Warrants	216	(216)	-	-	=	
	550,998	(216)	(184,040)	44,140	(292,389)	118,493

4. Investment in Associates

The following table outlines the carrying amount of the investments in associates as of May 31, 2023:

	1	NeonMind	La	ancaster	Total
Carrying value of investment, November 30, 2021	\$	1,702,187	\$	150,621	\$ 1,852,808
Disposals		-		(43,672)	(43,672)
Proportionate net loss		(518,746)		(83,843)	(602,589)
Carrying value of investment, November 30, 2022		1,183,441		23,106	1,206,547
Disposals		-		(126)	(126)
Proportionate net income (loss)		19,757		(22,980)	(3,223)
Carrying value of investment, May 31, 2023	\$	1,203,198	\$	-	\$ 1,203,198

Investment in NeonMind Biosciences Inc. ("NeonMind")

NeonMind is a company engaged in drug development research into potential therapeutic uses of psychedelic compounds. On April 18, 2022, NeonMind effected a 4:1 share consolidation and on January 24, 2023, NeonMind effected a 30:1 share consolidation. All share and per share amounts in these financial statements have been retroactively adjusted for the share consolidation.

The Company has determined that it has significant influence in NeonMind as it held 276,925 representing 24.7% of the voting rights in NeonMind as of May 31, 2023 (November 30, 2022 – 22.9%). The Company's investment in NeonMind was accounted for as an investment in associate using the equity method. The equity method involves recording the initial investment at cost and subsequently adjusting the carrying value of the investment for the Company's proportionate share of the profit or loss, other comprehensive income or loss and any other changes in the associate's net assets, such as further investments or dividends.

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

4. Investment in Associates (continued)

The Company has the same reporting date as NeonMind and was provided with the unaudited financial information of NeonMind for the period from December 1 to May 31, 2023 and 2022 to calculate the portion of net loss attributable to the Company.

The following tables summarize the unaudited financial information of NeonMind:

	Neo	nMi	nd	_		
	May 31,	No	ovember 30,			
	2023		2022			
Cash	\$ 255	\$	35,817	_		
Current and total assets	83,354		129,430			
Current liabilities	288,603		684,488			
Total liabilities	1,303,288		1,531,425			
	Three months ended			Six mont	hs ended	
	 May 31,				May	/ 31,
	2023		2022		2023	2022
Net income (loss)	\$ (84,308)	\$	900,118	\$	140,649	\$(1,781,672)

Investment in Lancaster Resources Inc. ("Lancaster")

Lancaster's principal business is to acquire, explore, and develop mineral properties and ultimately seek earnings by exploiting mineral claims. Currently, the Company is evaluating and reviewing potential resource properties and other business opportunities as possible options or joint ventures.

As of May 31, 2023, the Company held 1,750,000 (November 30, 2022 - 2,000,000) shares of Lancaster, which represented 8.5% (November 30, 2022 – 10.5%) ownership in Lancaster. The corporate secretary of the Company is a director of Lancaster who represents 33.3% of the board of Lancaster. The Company determined that it has significant influence in Lancaster. The Company's investment in Lancaster is accounted for as an investment in associate using the equity method.

The Company does not have the same reporting date as its associate. The Company was provided with unaudited financial statements for three and six months ended May 31, 2023 and 2022 to calculate the portion of net loss attributable to the Company.

The unaudited financial information of Lancaster as of May 31, 2023 and November 30, 2022:

		Land	cast	er	_	
		May 31,	No	vember 30,	-	
		2023		2022	_	
Cash	\$	410,357	\$	23,651	-	
Current assets		736,709		187,272		
Total assets		1,007,839		221,033		
Current and total liabilities		45,670		109,637		
	Three montl May				Six months e	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		2023		2022	2023	2022
Net loss	\$ ((1,461,353)	\$	(165,689)	\$(1,881,826) \$	(165,689)

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

5. Right-of-use Assets and Lease Liabilities

The Company's office lease was recognized as a lease liability of \$229,117 and associated right-of-use asset of \$182,362 upon the adoption of IFRS 16 *Leases* on December 1, 2019. Effective July 1, 2022, the Company entered into a sublease agreement, whereby the subtenant shall lease the entire office from the Company. The term of the sublease agreement represents the remainder of the head lease agreement and expires on March 31, 2023. Upon entering the sublease agreement, in accordance with IFRS 16 *Leases*, the Company derecognized the right-of-use asset associated with the office lease, which had a net book value of \$41,031, and recognized the net investment in sublease of \$87,313. The difference of \$46,282 between the right-of-use asset and net investment in sublease was recognized as a gain on sublease agreement on the consolidated statement of operations and comprehensive loss during the year ended November 30, 2022. As at May 31, 2023, the Company do not have any leases. As May 31, 2023, the Company's lease liabilities are as follows:

	Office	Wa	arehouse	Total
Lease liabilities, November 30, 2021	\$ 110,464	\$	192,773	\$ 303,237
Lease payments	(92,548)		(31,912)	(124,460)
Lease interest	11,932		13,531	25,463
Disposals	=		(174,392)	(174,392)
Lease liabilities, November 30, 2022	29,848		-	29,848
Lease payments	(30,748)		-	(30,748)
Lease interest	900		-	900
Lease liabilities, May 31, 2023	\$ -	\$	-	\$ -
Current portion	-		-	-
Non-current portion	=		-	
	\$ -	\$	-	\$ -

6. Leasehold Improvements

	Phone		Leasehold	
and display	equipment	Equipment	improvements	Total
160,609	2,378	43,517	76,594	385,721
(160,609)	(2,378)	(43,517)	-	(309, 127)
-	-	-	76,594	76,594
-	-	=	-	-
			76,594	76,594
122,496	1,706	16,817	43,058	279,105
24,705	237	4,108	25,328	56,485
(147,201)	(1,943)	(20,925)	-	(267, 204)
-	-	-	68,386	68,386
-	-	=	8,208	8,208
-	-	=	76,594	76,594
			8,208	8,208
			_	
	160,609 (160,609) - - - 122,496 24,705	and display equipment 160,609 2,378 (160,609) (2,378) 122,496 1,706 24,705 237	and display equipment Equipment 160,609 2,378 43,517 (160,609) (2,378) (43,517) - - - <t< td=""><td>and display equipment Equipment improvements 160,609 2,378 43,517 76,594 (160,609) (2,378) (43,517) - - - - 76,594 - - - - - - - - 122,496 1,706 16,817 43,058 24,705 237 4,108 25,328 (147,201) (1,943) (20,925) - - - 68,386 - - 8,208 - - 76,594</td></t<>	and display equipment Equipment improvements 160,609 2,378 43,517 76,594 (160,609) (2,378) (43,517) - - - - 76,594 - - - - - - - - 122,496 1,706 16,817 43,058 24,705 237 4,108 25,328 (147,201) (1,943) (20,925) - - - 68,386 - - 8,208 - - 76,594

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

7. Convertible Debentures

Carrying amount of liability at November 30, 2021 Accrued interest Accretion	\$ \$	627,614 44,878 74,258
Carrying amount of liability at May 31, 2022		746,750
Carrying amount of liability at November 30, 2022 Accrued interest Accretion		851,513 44,876 80,509
Carrying amount of liability at May 31, 2023	\$	976,898

On August 31, 2021, the Company issued 90 convertible debenture units at a price of \$10,000 per unit for gross proceeds of \$900,000. Each unit consists of a repayable note with a value of \$10,000 (the "Debentures") and 12,500 warrants to purchase common shares of the Company. The Debentures bear interest at a rate of 10% per annum on an accrual basis from issuance, calculated and payable semi-annually in arrears on May 31 and November 30 of each year. The fair value of the warrants was estimated to be \$72,440, using the Black-Scholes Pricing model with the following assumptions: stock price at grant date of \$0.55; an annualized volatility of 120%; an expected life of 3 years; a dividend yield of 0%; an expected forfeiture rate of 0%; and a risk-free rate of 53%.

The Debentures have a redemption date that is 24 months from the date of issuance and are convertible in full or in part, at the holders' option, into common shares of the Company at a price of \$0.80 per common share, at any time prior to their redemption. Each warrant entitles the holder thereof to acquire one common share of the Company at a price of \$1.10 per share for a period of 36 months from the date of issue.

In connection with the issuance of the Debentures, the Company paid broker fees of \$85,840, commission fees of \$81,000 and granted 101,250 agent's options (the "Agent's Options") with a fair value of \$36,195 entitling the holder to purchase a unit of the Company (the "Agent's Option Unit") at \$0.80 per Agent's Option until August 31, 2024. Each Agent's Option Unit consists of one common share of the Company (each, an "Agent's Option Share") and one share purchase warrant (each, an "Agent's Option Warrant"). Each Agent's Option Warrant further entitles the holder to purchase one additional common share of the Company at a price of \$1.10 for a period of 36 months from the Agent's Options issue date of August 31, 2021. The estimated fair value associated with the Agent's Options granted was determined using the Black-Scholes Pricing model with the following assumptions: stock price at grant date of \$0.55; an annualized volatility of 120%; an expected life of 3 years; a dividend yield of 0%; an expected forfeiture rate of 0%; and a risk-free rate of 0.53%.

The gross proceeds of \$900,000 of the Debentures were separated into the liability component of \$762,500, and the equity component of \$137,500 using the effective interest rate method with an effective interest rate of 20% per annum. The equity component is comprised of \$65,060 pertaining to the conversion feature and \$72,440 pertaining to the warrants attached to the Debentures.

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

7. Related Party Transactions

During the three and six months ended May 31, 2023 and 2022, compensation of key management personnel and directors were as follows:

	Three month	s ended	Six months ended	
	May 31,		May 31,	
	2023	2023 2022		2022
Consulting fees	\$11,500	\$88,950	\$38,734	\$169,518
Share-based compensation	134	70,250	583	124,833
Wages	-	279,725	-	620,256
	\$11,634	\$438,925	\$39,317	\$914,607

At May 31, 2023, the Company owed \$10,200 (November 30, 2022 - \$5,800) to the Chief Executive Officer of the Company, which is included in due to related parties. These amounts are unsecured and non-interest bearing.

At May 31, 2023, the Company owed \$60,750 (November 30, 2022 - \$32,750) to the Chief Financial Officer of the Company, which is included in due to related parties. These amounts are unsecured and non-interest bearing.

During the six months ended May 31, 2023, the Company recognized revenue of \$12,250 (2022 - \$85,920) from an associated company, NeonMind. As at May 31, 2023, the Company was owed \$9,414.21 (November 30, 2022 – was owed \$7,553) by NeonMind, which is included in due from related parties.

During the six months ended May 31, 2023, the Company recognized consulting revenue of \$10,000 (2022 - \$57,809) from an associated company, Lancaster. As at May 31, 2023, the Company owed \$414 to (November 30, 2022 - owed \$8,741 to) Lancaster and held a \$50,000 (November 30, 2022 - \$50,000) deposit for services from Lancaster, which are included in due to related parties.

During the three and six months ended May 31, 2023, the Company settled a loan of \$100,000 with Tevera Energy Corp. which amalgamated into Lancaster in March 2023, by returning 500,000 common shares of Lancaster that the Company owned valued at \$0.20 per share.

9. Share Capital

Authorized: unlimited number of common shares without par value.

On January 24, 2022, the Company effected a 10:1 share consolidation. All share and per share amounts in these condensed interim consolidated financial statements have been retroactively adjusted for the share consolidation.

At May 31, 2023, the Company has 19,917,970 common shares issued and outstanding.

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

10. Share Purchase Warrants

The following table summarizes the continuity of the Company's share purchase warrants:

	Number of	Weighted average
	warrants	exercise price
Balance, November 30, 2021	5,576,840	\$ 1.40
Expired	(3,784,590)	0.98
Balance, November 30, 2022 and May 31, 2023	1,792,250	\$ 2.30

As at May 31, 203, the following share purchase warrants were outstanding:

Number of warrants			
outstanding	Exerc	cise price	Expiry date
546,000	\$	5.00	October 30, 2023
20,000	\$	3.40	January 3, 2024
101,250	\$	0.80	August 31, 2024
1,125,000	\$	1.10	August 31, 2024
1,792,250			

11. Stock Options

On May 15, 2017, the Company adopted an incentive stock option plan. Pursuant to the Company's stock option plan, directors may, from time to time, authorize the issuance of options to directors, officers, employees, and consultants of the Company. The terms of the granted stock options as well as the vesting conditions are at the sole discretion of the directors. The following table summarizes the continuity of the Company's stock options:

		Weighted
	Number of	average
	options	exercise price
Outstanding, November 30, 2021	1,966,983	\$2.79
Granted	430,000	
Expired	(638,573)	
Cancelled	(661,600)	
Forfeited	(257,809)	
Outstanding, November 30, 2022	839,001	\$1.39
Expired	(118,200)	
Outstanding, May 31, 2023	720,801	\$1.28
Exercisable, May 31, 2023	715,801	\$1.27

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

11. Stock Options (continued)

Additional information regarding stock options outstanding and exercisable as at May 31, 2023, is as follows:

Range of			Weighted average
exercise	Stock options	Stock options	remaining contracted
prices	outstanding	exercisable	life (years)
\$ 0.20 - 0.99	320,000	320,000	3.69
\$ 1.00 – 1.99	338,500	333,500	2.42
\$ 2.00 – 2.99	15,800	15,800	1.60
\$ 5.00 – 5.99	6,501	6,501	0.74
\$ 7.00 – 7.99	40,000	40,000	0.73
	720,801	715,801	2.86

Share-based compensation expense is determined using the Black-Scholes option pricing model. During the six months ended May 31, 2023, the Company recognized share-based compensation expense of \$829 (2022 - \$67,472) in equity reserves, of which \$449 (2022 - \$65,767) pertains to directors and officers of the Company. There were no stock options granted or exercised during the six months ended May 31, 2023. Weighted average assumptions used in calculating the fair value of share-based compensation expense, assuming no expected dividends or forfeitures, are as follows:

2023	2022
1.68%	1.68%
0%	0%
133%	133%
4.94	4.94
	0% 133%

As at May 31, 2023, there was \$417 (November 30, 2022 - \$1,080) of unrecognized share-based compensation related to unvested stock options.

12. Loss of Control and Disposal of Subsidiary

On February 14, 2022, the Company dissolved its wholly owned subsidiary, W&W Manufacturing (Note 22). As a result of deregistering the former subsidiary, the Company fully derecognized its previous investment in W&W Manufacturing. W&W Manufacturing's assets and liabilities were primarily due to/due from intercompany; therefore the dissolution did not have a material impact on the consolidated statement of operations and comprehensive loss for the three and six months ended May 31, 2022.

On April 12, 2022, the Company sold certain assets of its formerly wholly owned subsidiary, Jusu Wellness. The Company derecognized the assets and liabilities of Jusu Wellness included in the sale, which had a net negative balance of \$101,599. Additionally, the Company derecognized the contingent consideration of \$31,420 associated with the original purchase of Jusu. This contingent consideration was payable in the form of 2,500,000 units of the Company if within three years, the quarterly or annual financial statements for any period indicate that the Company as generated \$5 million in gross revenues through the sale of Jusu products. As the Company no longer sells Jusu products, it will not be meeting the criteria of the contingent consideration.

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

12. Loss of Control and Disposal of Subsidiary (continued)

The loss on disposal of the subsidiary was calculated as follows:

	April	12, 2022
Consideration received	\$	1
Carrying value of assets disposed of		244,081
Liabilities assumed by purchaser		(142,483)
Net	\$	101,599

13. Capital Management

The Company manages its capital structure and makes adjustments, based on the funds available to the Company, to support the general operations of the Company and facilitate the liquidity needs of its operations. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company defines capital to include its working capital position, share capital, special warrant reserve, and equity reserves.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the three and six months ended May 31, 2023. The Company is not subject to externally imposed capital requirements.

14. Investment Income (Loss)

	Three months ended		Six months ended	
	May 31,		May 31,	
	2023	2022	2023	2022
Realized gain on marketable securities	\$ (1,875)	\$ - \$	(1,875)	\$ 43,924
Unrealized gain (loss) on marketable securities	(15, 182)	(140,039)	(47,498)	(292,389)
Gain on sale of equity accounted investee	-	-	-	130,000
Dilution gain on equity accounted investee	-	-	-	17,173
Share of net income (loss) of equity accounted investees	(19,242)	(260,719)	(3,222)	(512,284)
	\$ (36,299)	\$ (400,758) \$	(52,595)	\$ (613,576)

15. Other Income (Expenses)

	Three months ended S May 31,	Six months ended May 31,
	2023 2022	2023 2022
Loss on loss of control of subsidiaries	\$ - \$(21,099) \$	- \$ (21,099)
Gain on disposal of assets		- 1,200
Loss on foreign exchange	0 (213)	(2,031) (466)
Interest and accretion	(62,928) (65,333) (1	25,110) 28,377
Gain on debt settlement	99,999 28,377 2	31,255 (130,916)
	\$ 37,071 \$ (58,268) \$ 1	04,114 \$(122,904)

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

16. Financial Instruments and Risk Management

Fair Values

Assets and liabilities measured at fair value on a recurring basis were presented on the Company's consolidated statement of financial position as at May 31, 2023, as follows:

	Fair Value				
	Quoted prices in		Significant		
	active markets for	Significant other	unobservable	Balanc	е
	identical instruments	observable inputs	inputs	May 31	١,
	(Level 1)	(Level 2)	(Level 3)	2023	
Marketable securities	\$ 22,007	\$ -	\$ -	\$ 22	2,007

The fair values of other financial instruments, including cash, accounts receivable, accounts payable and accrued liabilities, lease liabilities, loans payable, and amounts due from and to related parties, approximate their carrying values due to the relatively short-term maturity of these instruments.

Credit Risk

Credit risk is the risk of loss that may arise on outstanding financial instruments should a counter-party default on its obligation. The Company's credit risk is primarily attributable to accounts receivable. The Company minimizes its credit risk associated with its cash balance by dealing with major financial institutions in Canada, and has no other significant concentration of credit risk arising from operations. Accounts receivable is primarily comprised of trade accounts receivable. For accounts receivable, the Company limits its exposure to credit risk by dealing with what management believes to be financially sound counter parties. The carrying amount of financial assets represents the maximum credit exposure.

Foreign Exchange Rate and Interest Rate Risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to the changes in foreign exchange rates. The Company is not exposed material foreign exchange rate and interest rate risks.

Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting financial obligations due to shortage of funds. The Company manages liquidity risk by maintaining sufficient cash balances and adjusting its operating budget and expenditure. Liquidity requirements are managed based on expected cash flows to ensure that there are sufficient funds to meet short-term and specific obligations.

Price Risk

The Company is exposed to price risk with respect to its marketable securities, which consists of common shares held in publicly traded companies and is dependent upon the market price or the fair value of the common shares for those companies. The market price or the fair value of the common shares of those companies can fluctuate significantly, and there is no assurance that the future market price or the fair value of those companies will not decrease significantly.

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

16. Discontinued Operations

On April 20, 2022, the Company sold its wholly owned subsidiary, Jusu. The sale includes existing liabilities and ongoing obligations, plus all inventory, packaging, raw ingredients, and intellectual property related to Jusu Wellness' products, the e-Commerce site, and consumer lists. The consideration received for the said was \$1 plus assumption of current and future liabilities.

During the year ended November 30, 2022, the Company wound down the operations of Jusu Bars and Urban Juve. On April 12, 2022, Jusu Bars and Urban Juve were amalgamated and renamed Metaversive Holdings, resulting in all assets and liabilities being transferred into Metaversive Holdings.

On February 14, 2022, the Company dissolved its wholly owned subsidiary, W&W Manufacturing.

No transaction from discontinued operations was recorded for the three and six months ended May 31, 2023. The statement of operations from the discontinued operation for the three and six months ended May 31, 2022 is as follows:

	Thi	ree monthes ended	Six month		
	May 31, 2022		May 31	May 31, 2022	
Revenue	\$	19,228	\$	99,734	
Cost of revenues		1,154		32,986	
Gross profit		18,074		66,748	
Advertising, marketing and media		2,503		18,368	
Amortization and depreciation		16,431		40,176	
Office and administrative		20,058		35,041	
Product development, research and registration		-		(5,893)	
Professional fees		7,800		12,444	
Selling costs		27,864		54,020	
Wages		6,689		134,415	
Net loss before other items		(63,954)		(222,506)	
Inventory write-offs and donations		-		(81,778)	
Interest and accretion		(6,371)		(16,010)	
Foreign exchange gain/loss		160		(22,901)	
Net loss for the period	\$	(101,759)	\$	(374,789)	

18. Commitments and Contingencies

Commitments

The Company's annual contractual commitments for the next five years related to these items are as follows:

		Payments Due by Period				
	1 Year	2-3 Years	4-5 Years	Total		
Loans	\$ 80,000	_	_	\$ 80,000		
Convertible debentures	976,899	_	_	976,899		
	\$ 1,056,899	\$ -	\$ -	\$ 1,056,899		

Notes to the Condensed Interim Consolidated Financial Statements For the three and six months ended May 31, 2023 (Expressed in Canadian Dollars) (Unaudited)

18. Commitments and Contingencies (continued)

Loan:

The Company received an interest free Canada Emergency Business Account loan of \$120,000. If the Company repays \$80,000 by December 31, 2023 the remaining \$40,000 will be forgiven. If any portion of the loan is unpaid by December 31, 2023, the balance of the loan will convert to a 5% interest term loan with extended maturity to December 31, 2025.

Convertible debentures:

The debenture holders have the option at any time prior to the maturity date on August 31, 2023, to convert in whole or in part being \$1,000 or an integral multiple thereof, of the principal amount of the Debenture into common shares of the Company. On maturity, the Company shall satisfy its obligation to pay the principal amount of the Debentures which have matured in cash.

Contingencies:

On February 26, 2021, a claim was commenced against the Company and 8931429 Canada Inc. (formerly Jusu Bars Inc.), which sold its assets to the Company during the year ended November 30, 2020, regarding the failure of 8931429 Canada Inc., to pay rent on its retail unit located in Calgary, Alberta. The landlord is seeking payment for the amounts owing in arrears and damages for breach of contract. As the damages claimed by the plaintiff were not directly against the Company, the Company believes this claim lacks merit and intends to defend this claim. Due to the uncertainty of timing and the amount of estimated future cash outflows relating to this claim, no provision has been recognized.